Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Dane, Faysal; Ozgurdal, Kirhan; YALÇIN, ŞUAYİB; BENEKLİ, MUSTAFA; Aykan, Nuri; YÜCEL, İDRİS; ÖZKAN, METİN; EVRENSEL, TÜRKKAN; Sevinc, Alper; COŞKUN, HASAN; ŞANLI, ULUS; KARA, İSMAİL; Yumuk, Perran

doi:10.1136/bmjopen-2018-027665

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Copy For Citation

Dane F., Ozgurdal K., YALÇIN Ş., BENEKLİ M., Aykan N. F., YÜCEL İ., ...More

BMJ OPEN, vol.10, no.3, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 10 Issue: 3
Publication Date: 2020
Doi Number: 10.1136/bmjopen-2018-027665
Journal Name: BMJ OPEN
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
Hacettepe University Affiliated: Yes

Abstract

Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC.